FDA to review Merck's treatment for ragweed pollen allergy

05/10/2013 | Fox Business

The FDA has accepted Merck & Co.'s biologics-license application for a dissolvable immunotherapy tablet for ragweed pollen allergy. Merck expects the FDA to release its decision in the first half of next year. The sublingual tablet was developed in collaboration with ALK-Abello.

View Full Article in:

Fox Business

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President, Science and Regulatory Affairs
American Beverage Association
Washington, DC
Senior Manager of Medical Management
Network Health
Medford, MA
MEDICAL SCIENCE LIAISON - 14000002RO
Abbott
Columbus, OH
Manager, Medical Management
Network Health
Medford, MA
Executive Medical Director
Aspirus Network Inc
Wausau, WI